Ho Kyung Seo

机构：National Cancer Center, National Cancer Center · ORCID：0000-0003-2601-1093

发表论文 227 篇 · 总被引 3280 次 · h-index 27

代表论文

• Pembrolizumab monotherapy for high-risk non-muscle-invasive bladder cancer without carcinoma in situ and unresponsive to BCG (KEYNOTE-057): a single-arm, multicentre, phase 2 trial (2024 · The Lancet Oncology · 被引 95)
• Erdafitinib versus pembrolizumab in pretreated patients with advanced or metastatic urothelial cancer with select FGFR alterations: cohort 2 of the randomized phase III THOR trial (2023 · Annals of Oncology · 被引 84)
• Erdafitinib in BCG-treated high-risk non-muscle-invasive bladder cancer (2023 · Annals of Oncology · 被引 83)
• Approaches to Clinical Complete Response after Neoadjuvant Chemotherapy in Muscle-Invasive Bladder Cancer: Possibilities and Limitations (2023 · Cancers · 被引 22)
• Advances in Therapy for Urothelial and Non-Urothelial Subtype Histologies of Advanced Bladder Cancer: From Etiology to Current Development (2025 · Biomedicines · 被引 15)
• Avelumab first-line maintenance treatment in patients with locally advanced or metastatic urothelial carcinoma: real-world results from a Korean expanded access program (2024 · Frontiers in Oncology · 被引 13)